Business Context and Reporting Period
This Form 8-K was filed by AnaptysBio, Inc. on March 19, 2018. The report addresses a corporate governance event involving the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Director Resignation: James A. Schoeneck resigned as a Class III independent director and as a member of the audit and compensation committees, effective immediately on March 19, 2018.
- Reason for Departure: The resignation is for personal reasons and is not the result of any disagreement with AnaptysBio regarding operations, policies, or practices.
- Committee Appointment: Following the resignation, Dennis Fenton, Ph.D., was appointed to the audit committee.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, or management commentary regarding future financial performance. No risks, contingencies, or unusual items were disclosed in this specific report.
Investor Verification Checklist
- Verify the composition of the Board of Directors and the Audit Committee following the appointment of Dr. Dennis Fenton.
- Confirm that the resignation of Mr. Schoeneck was indeed for personal reasons and unrelated to any undisclosed corporate disputes.
- Review subsequent filings for any impact on the company's governance structure or audit oversight.